BioCentury
ARTICLE | Company News

Verastem, Merck, Cancer Research UK deal

October 10, 2016 7:00 AM UTC

The companies partnered to conduct an open-label, dose-escalation, U.K. Phase Ib/IIa trial to evaluate Verastem’s defactinib ( VS-6063) in combination with Merck’s cancer drug Keytruda pembrolizumab ...